Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

(Bloomberg) -- Novo Nordisk A/S is cutting back on recruiting ... In the US, Novo is building both its research and development and manufacturing workforce, he said. “There will be a slowdown ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

The biotech went public via a $278 million IPO in 2020. Novo Nordisk said the deal ties in with its strategy of building a position in haemaglobinopathies, a group of disorders that includes SCD ...

Novo Nordisk execs claim the system will be ... drugs have earned into an AI-based supercomputer. The cost of building the supercomputer was not disclosed. The company has contracted Eviden ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Globally, Novo Nordisk holds 65% of the market for GLP ... The company's ability to produce the next generation of weight loss medicines building on the success of Wegovy is now deeply in question.